Optimal management of severe/refractory asthma

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Volumn 5, Issue 1, 2011, Pages 37-47

  Pakhale, Smita ^a,b   Mulpuru, Sunita ^a   Boyd, Matthew ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Asthma management; Difficult asthma; Refractory asthma; Severe asthma

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CLARITHROMYCIN; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE; GOLIMUMAB; INFLUENZA VACCINE; ITRACONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; OMALIZUMAB; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISOLONE; PROTON PUMP INHIBITOR; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE;

ADD ON THERAPY; ADRENAL SUPPRESSION; ALLERGIC ASTHMA; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANAPHYLAXIS; ASTHMA; BONE DENSITY; BRONCHIAL THERMOPLASTY; BRONCHOSCOPY; COMORBIDITY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPHONIA; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HUMAN; INFLUENZA VACCINATION; INJECTION SITE REACTION; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; NON INVASIVE PROCEDURE; NONHUMAN; OBESITY; OROPHARYNX CANDIDIASIS; PARASITOSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PEAK EXPIRATORY FLOW; PREVALENCE; REVIEW; SELF CARE; SIDE EFFECT; SLEEP APNEA SYNDROME; SMOKING CESSATION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 80053908044     PISSN: 11795484     EISSN: 11795484     Source Type: Journal    
DOI: 10.4137/CCRPM.S5535     Document Type: Review

References (101)

1. Holgate ST, Arshad HS, Roberts GC, Howarth PH, Thurner P, Davies DE. A new look at the pathogenesis of asthma. Clinical Science. 2010;118(7): 439-50.
2. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181(4):315-23.
3. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2):405-13.
4. Wenzel SE, Busse WW. Severe asthma: Lessons from the Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(1):14-21.
5. Moore WC, Peters SP. Severe asthma: An overview. J Allergy Clin Immunol. 2006;117(3):487-94.
6. Wenzel SE. Severe asthma and its phenotype. Journal of Asthma. 2008; 45(Suppl 1):32-6.
7. Boulet LP, Chapman KR. Asthma Education: the Canadian Experience. Chest. 1994;106(Suppl 4):206S-10.
8. CDC Morbidity and Mortality Weekly report: Vital Signs: Asthma Prevalence, Disease Characteristics, and Self-Management Education-United States, 2001-2009. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6017a4.htm?s_cid=mm6017a4_w.2011.
9. Hargreave FE, Nair P. The definition and diagnosis of Asthma. Clin Exp Allergy. 2009;39(11):1652-8.
10. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). (Survey). Thorax. 2007;62(9):758.
11. Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001-2009. MMWR Morb Mortal Wkly. Rep 2011;60(17):547-52.
12. http://www40.statcan.ca/l01/cst01/health49b.htm. 11-8-2008.
13. Beuther DA, Sutherland ER. Overweight, Obesity, and Incident Asthma: A Meta-analysis of Prospective Epidemiologic Studies. Am J Respir Crit Care Med. 2007;175(7):661-6.
14. Boulet LP, Becker A, Bérubé D, Beveridge R, Ernst P. Canadian asthma consensus report. 1999. CMAJ. 1999;161:S1-62.
15. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143-78.
16. Wenzel SE, Busse WW. Severe asthma: Lessons from the Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(1):14-21.
17. Ernst P, Fitzgerald JM, Spier S. Canadian Asthma Consensus Conference Summary of recommendations. Can Respir J. 1996;3(2):89-114.
18. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol. 1996;98(6 Pt1):1016-8.
19. Proceedings of the ATS Workshop on Refractory Asthma. Current Understanding, Recommendations, and Unanswered Questions. Am J Respir Crit Care Med. 2000;162(6):2341-51.
20. Barnes PJ, Woolcock AJ. Difficult asthma. European Respiratory Journal. 1998;12(5):1209-18.
21. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. European Respiratory Journal. 1996;9(4):636-42.
22. Aaron SD, Vandemheen KL, Boulet LP, McIvor RA, Fitzgerald JM, Hernandez P. et al. Overdiagnosis of asthma in obese and nonobese adults. Can Med Assoc J. 2008;179(11):1121-31.
23. http://www.on.lung.ca/page.aspx?pid=420.http://www.on.lung.ca/page.aspx?pid=420. 2011.
24. Reid RD, Quinlan B, Riley DL, Pipe AL. Smoking cessation: lessons learned from clinical trial evidence. Curr Opin Cardiol. 2007;22(4).
25. Mackay D, Haw S, Ayres JG, Fischbacher C, Pell JP. Smoke-free Legislation and Hospitalizations for Childhood Asthma. N Engl J Med. 2010;363(12):1139-45.
26. Gamble J, Stevenson M, McClean E, Heaney LG. The Prevalence of Nonadherence in Difficult Asthma. Am J Respir Crit Care Med. 2009;180(9): 817-22.
27. Gamble J, Stevenson M, Heaney LG. A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respiratory Medicine 2011; In Press, Corrected Proof.
28. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997; 46(RR-8):1-24.
29. Talbot TR, Hartert TV, Mitchel E, Halasa NB, Arbogast PG, Poehling KA, et al. Asthma as a Risk Factor for Invasive Pneumococcal Disease. New England Journal of Medicine. 2005;352(20):2082-90.
30. Lessard A, Turcotte H, Cormier Y, Boulet LP. Obesity and Asthma: A Specific Phenotype? Chest. 2008;134(2):317-23.
31. Boulet LP. Influence of comorbid conditions on asthma. N Engl J Med. 2009;33(4):897-906.
32. Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma. The American Lung Association Asthma Clinical Research Centers. New England Journal of Medicine. 2009;360(15):1487-99.
33. Chan WW, Chiou E, Obstein KL, Tignor AS, Whitlock TL. The Efficacy of Proton Pump Inhibitors for the Treatment of Asthma in Adults: A Meta- analysis. Arch Intern Med. 2011;171(7):620-9.
34. Lugogo NL, Kraft M, Dixon AE'. Does Obesity Produce a Distinct Asthma Phenotype? J Appl Physiol. 2009;00845.
35. Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund EL, Ylikahri M, Mustajoki P. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ. 2000;320(7238):827-32.
36. Boulet LP, Hamid Q, Bacon SL, Bergeron C, Boulet LP, Chen Y, et al. Symposium on obesity and asthma-November 2, 2006. Can Respir J. 2007;14(4):201-8.
37. Lavoie KL, Bacon SL, Barone S, Cartier A, Ditto B, Labrecque M. What Is Worse for Asthma Control and Quality of Life: depressive disorders, anxiety disorders, or both?. Chest. 2006;130(4):1039-47.
38. Bosley CM, Fosbury JA, Cochrane GM. The psychological factors associated with poor compliance with treatment in asthma. European Respiratory Journal. 1995;8(6):899-904.
39. Tonnel AB, Tillie-Leblond I. Refractory asthma: diagnosing allergic bronchopulmonary aspergillosis. Presse Med. 2008;37(1 Pt 2):161-6.
40. Gaga M, Zervas E, Gibson PG. Allergic and nonallergic factors in severe asthma. In: Chung KF, Bel EH, Wenzel SE, editors. Difficult-to-Treat Severe Asthma. European Respiratory Monograph. 2011:107-19.
41. Custovic A, van Wijk RG. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA2LEN). Allergy. 2005;60(9):1112-5.
42. Zureik M, Neukirch C, Leynaert B, Liard R, Bousquet J, Neukirch F. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ. 2002;325(7361):411.
43. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;(8):CD001186.
44. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma. New England Journal of Medicine. 2010;363(18):1715-26.
45. Lougheed MD, Lemiere C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, et al. Canadian Thoracic Society Asthma Management Continuum2010 Consensus Summary for children six years of age and over, and adults. Can Respir J. 2010;17(1):15-24.
46. Barnes PJ. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. J Allergy Clin Immunol. 1998; 101(Suppl 4):S427-33.
47. Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL. A comparison of fluticasone propionate, 1mg daily, with beclomethasone dipropionate, 2mg daily, in the treatment of severe asthma. Eur Respir J. 1993; 6:877-84.
48. Fluticasone: Drug information. http://www.uptodate.com/contents/fluticasone-drug-information?source=search_result&selectedTitle=180. 2011.
49. Lipworth BJ. Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis. Arch Intern Med. 1999;159(9): 941-55.
50. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (Full Report 2007). http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdfNIHpublication no.08-4051. 2011. Bethesda, MD.
51. Noonan M, Chervinsky P, Busse WW, Weisberg SC, Pinnas J, de Boisblanc BP, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med. 1995;152(5):1467-73.
52. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. British Medical Journal. 323[7307], 253. 4-8-2001.
53. Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidencebased approach. Med J Aust. 2003;178(5):223-5.
54. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. New England Journal of Medicine. 1997;337(20):1405-11.
55. Nelson HS, Busse WW, deBoisblanc BP, Berger WE, Noonan MJ, Webb DR, et al. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol. 1999;103(2 Pt 1):267-75.
56. Dean TP, Dewey A, Bara A, Lasserson TJ, Walters EH. Azathioprine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev CD003270. 2004.
57. Evans D, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev CD002993. 2001.
58. Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev CD002985. 2001.
59. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev CD000391. 2000.
60. Dean T, Dewey A, Bara A, Lasserson TJ, Walters H. Chloroquine as a steroid sparing agent for asthma. Cochrane Database Syst Rev CD003275. 2003.
61. Azuma A, Kudoh S. Diffuse panbronchiolitis in East Asia. Respirology. 2006;11(3):249-61.
62. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory Effects of Macrolide Antibiotics-Part 2: Advantages and Disadvantages of Long-Term, Low-Dose Macrolide Therapy. Respiration. 2011;81(1): 75-87.
63. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in Patients With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa. JAMA: J Allergy Clin Immunol. 2003;290(13):1749-56.
64. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. The Lancet. 2002;360(9338):978-84.
65. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57(3):212-6.
66. Kostadima E, Tsiodras S, Alexopoulos EI, Kaditis AG, Mavrou I, Georgatou N, et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal. 2004;23(5): 714-7.
67. Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA, et al. A trial of clarithromycin for the t{stroke}reatment of suboptimally controlled asthma. JAMA. 2010;126(4):747-53.
68. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin Targets Neutrophilic Airway Inflammation in Refractory Asthma. Am J Respir Crit Care Med. 2008;177(2):148-55.
69. Denning DW, O'Driscoll BR, Powell G, Chew F, Atherton GT, Vyas A, et al. Randomized Controlled Trial of Oral Antifungal Treatment for Severe Asthma with Fungal Sensitization: The Fungal Asthma Sensitization Trial (FAST) Study. Am J Respir Crit Care Med. 2009;179(1):11-8.
70. Gore RB. The utility of antifungal agents for asthma. Current Opinion in Pulmonary Medicine 2010;16(1).
71. Haselden BM, Kay AB, Larche M. Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol. 2000;122(4):229-37.
72. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Eng J Med. 1989;320:271-7.
73. D'Amato G, Piccolo A, Salzillo A, Noschese P, D'Amato M, Liccardi G. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma. Recent Pat Inflamm Allergy Drug Discov. 2007;1(3):225-31.
74. Bang LM, Plosker GL. Spotlight on Omalizumab in Allergic Asthma. BioDrugs. 2004;18:415-8.
75. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. The Journal of Immunology. 1993;151(5):2623-32.
76. Bang LM, Plosker GL. Spotlight on Omalizumab in Allergic Asthma. BioDrugs. 2004;18:415-8.
77. Beck LA, Marcotte GV, MacGlashan J, Togias A, Saini S. Omalizumabinduced reductions in mast cell Fc[epsilon]RI expression and function. Journal of Allergy and Clinical Immunology. 2004;114(3):527-30.
78. Omalizumab: Drug information. http://www.uptodate.com/contents/omalizumab-drug-information?source=see_link&utdPopup=true. 2011.
79. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safy and tolerability of omalizumab. Clinical & Experimental Allergy. 2009; 39(6):788-97.
80. US Food and Drug Administration: Postmark Drug Safy Information for Patients and Providers: Information for Healthcare Professionals: Omalizumab (marked as Xolair). http://www.fda.gov/Drugs/DrugSafy/PostmarkDrugSafyInformationforPatientsandProviders/ucm126456.htm. 2007.
81. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF,et al. Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma. Am J Respir Crit Care Med. 2004;170(6):583-93.
82. Zikowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A. Anti-IgE therapy with omalizumab decreases endothelin-1in exhaled breath condensate of patients with severe persistent allergic asthma. Respiration. 2010;80(6):534-42.
83. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H,et al. The antiIgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. European Respiratory Journal. 2001;18(2):254-61.
84. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. Journal of Allergy and Clinical Immunology. 2001;108(2):184-90.
85. Chipps B, Buhl R, Beeh KM, Fox H, Thomas K, Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin. 2006;22(11):2201-8.
86. Buhl R. Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review. Respir Med. 2003;97(2):123-9.
87. Humbert M, Beasley R, Ayres J, Slavin R, Hbert J, Bousqu J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002step 4 treatment): INNOVATE. Allergy. 2005;60(3):309-16.
88. Barnes PJ. Anti-IgE therapy. http://www.uptodate.com/contents/anti-ige-therapy. 2011.
89. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. Journal of Allergy and Clinical Immunology. 2004;114(2):265-9.
90. Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model. Journal of Allergy and Clinical Immunology. 2007;120(5):1146-52.
91. Wenzel SE, Barnes PJ, Bleecker ER, Bousqu J, usse W, Dhlen SE, et al. A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma. Am J Respir Crit Care Med. 2009;179(7):549-58.
92. Danek CJ, Lombard CM, Dungworth DL, Cox PG, Miller JD, Biggs MJ, et al. Reduction in airway hyperresponsiveness to mhacholine by the application of RF energy in dogs. Journal of Applied Physiology. 2004; 97(5):1946-53.
93. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, al. Asthma Control during the Year after Bronchial Thermoplasty. New England Journal of Medicine. 2007;356(13):1327-37.
94. Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, et al. Safy and Efficacy of Bronchial Thermoplasty in Symptomatic, Severe Asthma. Am J Respir Crit Care Med. 2007;176(12):1185-91.
95. Bel EH. Bronchial Thermoplasty: Has the Promise Been M? Am J Respir Crit Care Med. 2010;181(2):101-2.
96. Castro M, Rubin AS, Laviolte M, Fiterman J, Andrade LM, Shah PL, et al. Effectiveness and Safy of Bronchial Thermoplasty in the Treatment of Severe Asthma: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial. Am J Respir Crit Care Med. 2010;181(2): 116-24.
97. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, et al. Asthma Control during the Year after Bronchial Thermoplasty. New England Journal of Medicine. 2007;356(13):1327-37.
98. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Respiratory Journal. 2003;22(3):470-7.
99. Severe Asthma research Program (SARP). http://www.severeasthma.org/ SARP_home.html. 2011.
100. http://www.severeasthma.ca/. http://www.severeasthma.ca/. 2011.
101. Holgate S, Bisgaard H, Bjermer L, Haahtela T, Haughney J, Horne R, et al. The Brussels Declaration: the need for change in asthma management. Eur Respir J. 2008;32(6):1433-42.